Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 20, 2026, 4:04 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 515 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Liver Transplant Clear all
Recruiting Not applicable Interventional

Peer Support for Liver Transplant Recipients With History of ALD

NCT07397598
View directory record Official record
Conditions
Alcohol Use Disorder, Alcohol Related Liver Disease, Liver Transplant Recipient
Interventions
Peer Support
Behavioral
Lead sponsor
Johns Hopkins University
Other
Eligibility
18 Years and older
Enrollment
95 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Oct 6, 2026 · Synced Oct 20, 2026, 4:04 AM EDT
Completed Phase 3 Interventional Results available

Efficacy and Safety of Everolimus in Liver Transplant Recipients of Living Donor Liver Transplants

NCT01888432
View directory record Official record
Conditions
Liver Transplantation
Interventions
Everolimus + reduced tacrolimus, Standard tacrolimus
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
285 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2018
U.S. locations
9
States / cities
Los Angeles, California • San Francisco, California • Baltimore, Maryland + 6 more
Source: ClinicalTrials.gov public record
Updated Mar 18, 2019 · Synced Oct 20, 2026, 4:04 AM EDT
Completed Not applicable Interventional

Quality of Life Therapy for Adults With Hepatitis C Virus and Cirrhosis Awaiting Liver Transplantation

NCT00794911
View directory record Official record
Conditions
Chronic HCV
Interventions
Quality of Life Therapy, Supportive Therapy
Behavioral
Lead sponsor
Beth Israel Deaconess Medical Center
Other
Eligibility
21 Years to 70 Years
Enrollment
75 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2010
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Mar 15, 2017 · Synced Oct 20, 2026, 4:04 AM EDT
Terminated Phase 2 Interventional

A Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Antiviral Activity of ACH-0137171 in Participants With Chronic Hepatitis C Infection

NCT00401947
View directory record Official record
Conditions
HCV Infection
Interventions
ACH-0137171
Drug
Lead sponsor
Alexion Pharmaceuticals, Inc.
Industry
Eligibility
18 Years to 60 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2007
U.S. locations
7
States / cities
Phoenix, Arizona • La Jolla, California • San Francisco, California + 4 more
Source: ClinicalTrials.gov public record
Updated Sep 15, 2022 · Synced Oct 20, 2026, 4:04 AM EDT
Completed Phase 4 Interventional Results available

Evaluating Blood Glucose Levels During Infusion With HepaGam B (HBIG) in Post-liver Transplant Patients

NCT00998426
View directory record Official record
Conditions
Hepatitis B
Interventions
glucose monitoring before and after HepaGam B administration, HepaGam B (Hepatitis B Immune Globulin (HBIG))
Procedure · Biological
Lead sponsor
Georgetown University
Other
Eligibility
18 Years and older
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
1
States / cities
Washington D.C., District of Columbia
Source: ClinicalTrials.gov public record
Updated Sep 28, 2015 · Synced Oct 20, 2026, 4:04 AM EDT
Not listed Phase 4 Interventional

A Study of Thymoglobulin and Tacrolimus in Liver Transplant

NCT00564538
View directory record Official record
Conditions
Liver Transplantation, Liver Disease, Immunosuppression
Interventions
anti-thymocyte globulin (rabbit), tacrolimus
Drug
Lead sponsor
University of Nebraska
Other
Eligibility
19 Years and older
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
1
States / cities
Omaha, Nebraska
Source: ClinicalTrials.gov public record
Updated Nov 28, 2007 · Synced Oct 20, 2026, 4:04 AM EDT
Terminated Not applicable Interventional

Phase 2 Study of Ex-vivo Perfusion and Ventilation of Lungs to Assess Transplant Suitability

NCT01241942
View directory record Official record
Conditions
Emphysema, Chronic Obstructive Pulmonary Disease (COPD), Cystic Fibrosis, Pulmonary Fibrosis, Bronchiectasis, Sarcoidosis, Pulmonary Hypertension, Alpha-1 Antitrypsin Deficiency
Interventions
Steen Solution™, Conventional Lung Transplant
Device · Other
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
18 Years and older
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2013
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Jul 13, 2018 · Synced Oct 20, 2026, 4:04 AM EDT
Not listed Phase 2 Interventional

YSPSL for Prevention of Ischemic Reperfusion Injury in Patients Undergoing Cadaveric Orthotopic Liver Transplantation

NCT00876902
View directory record Official record
Conditions
Ischemia Reperfusion Injury
Interventions
recombinant P-selectin glycoprotein ligand Ig fusion protein, Viaspan® and saline
Drug
Lead sponsor
Y's Therapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Apr 7, 2009 · Synced Oct 20, 2026, 4:04 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Quantitative Susceptibility Mapping (QSM) to Guide Iron Chelating Therapy

NCT04171635
View directory record Official record
Conditions
MRI Scans
Interventions
Quantitative Susceptibility Mapping (QSM) Magnetic Resonance Imaging (MRI), R2* Magnetic Resonance Imaging (MRI)
Radiation
Lead sponsor
Weill Medical College of Cornell University
Other
Eligibility
2 Years and older
Enrollment
55 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2025
U.S. locations
2
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Feb 27, 2026 · Synced Oct 20, 2026, 4:04 AM EDT
Completed Not applicable Interventional Results available

Ex-vivo Perfusion and Ventilation of Lungs Recovered From Non-Heart-Beating Donors to Assess Transplant Suitability

NCT01615484
View directory record Official record
Conditions
Emphysema, Chronic Obstructive Pulmonary Disease (COPD), Cystic Fibrosis, Pulmonary Fibrosis, Bronchiectasis, Sarcoidosis, Pulmonary Hypertension, Alpha-1 Antitrypsin Deficiency
Interventions
Transplantation of lungs obtained from Non-Heart-Beating Donors (NHBDs) after ex-vivo perfusion w/ STEEN Solution™, STEEN Solution™
Procedure · Device
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
15 Years and older
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2017
U.S. locations
2
States / cities
Chapel Hill, North Carolina • Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Jun 8, 2018 · Synced Oct 20, 2026, 4:04 AM EDT
Completed Not applicable Interventional

Starzl Network Patient Reported Outcomes

NCT05241847
View directory record Official record
Conditions
Liver Transplant; Complications, Quality of Life, Child Behavior, Adolescent Behavior
Interventions
PeLTQL delivery via electronic means
Behavioral
Lead sponsor
University of Pittsburgh
Other
Eligibility
8 Years to 20 Years
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
6
States / cities
Oakland, California • Atlanta, Georgia • New York, New York + 2 more
Source: ClinicalTrials.gov public record
Updated Jan 8, 2026 · Synced Oct 20, 2026, 4:04 AM EDT
Not listed Not applicable Interventional

The Effect of Vitamin D Repletion in Patients With Hepatocellular Carcinoma on the Orthotopic Liver Transplant List

NCT01575717
View directory record Official record
Conditions
Vitamin D Deficiency, Hepatocellular Carcinoma
Interventions
Vitamin D3 4000 IU, Vitamin D3 2000 IU
Drug
Lead sponsor
Andrea Branch
Other
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Oct 24, 2012 · Synced Oct 20, 2026, 4:04 AM EDT
Terminated Not applicable Interventional Results available

Methacetin Breath Test in Patients With Liver Disease Secondary to Heart Disease

NCT04176458
View directory record Official record
Conditions
Dilated Cardiomyopathy, Tricuspid Atresia
Interventions
Methacetin Breath Test (MBT)
Device
Lead sponsor
Northwestern University
Other
Eligibility
18 Years and older
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Apr 5, 2023 · Synced Oct 20, 2026, 4:04 AM EDT
Completed Phase 2 Interventional Results available

Efficacy of Sofosbuvir With Ribavirin Administered Pre-Transplant in Preventing Hepatitis C Virus (HCV) Recurrence Post-Transplant

NCT01559844
View directory record Official record
Conditions
Hepatitis C, Hepatocellular Carcinoma
Interventions
Sofosbuvir, Ribavirin
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
18 Years and older
Enrollment
61 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
13
States / cities
Los Angeles, California • San Diego, California • San Francisco, California + 10 more
Source: ClinicalTrials.gov public record
Updated Jul 27, 2016 · Synced Oct 20, 2026, 4:04 AM EDT
Terminated Phase 4 Interventional Results available

Lung Transplantation in Chronic HCV Infection With Post Transplant EPCLUSA Treatment

NCT03207399
View directory record Official record
Conditions
Hepatitis C, Chronic, Lung Transplant
Interventions
Epclusa
Drug
Lead sponsor
Duke University
Other
Eligibility
18 Years and older
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Sep 11, 2019 · Synced Oct 20, 2026, 4:04 AM EDT
Not listed Not applicable Interventional

Contrast-Enhanced CT and MRI in Diagnosing and Staging Liver Cancer Using UNOS Policy

NCT01082224
View directory record Official record
Conditions
Liver Cancer
Interventions
iodinated contrast dye, motexafin gadolinium, Eovist-enhanced MRI
Drug · Other
Lead sponsor
American College of Radiology Imaging Network
Network
Eligibility
18 Years and older
Enrollment
440 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2023
U.S. locations
9
States / cities
Birmingham, Alabama • Scottsdale, Arizona • Los Angeles, California + 6 more
Source: ClinicalTrials.gov public record
Updated Jul 7, 2023 · Synced Oct 20, 2026, 4:04 AM EDT
Completed Phase 2 Interventional Results available

Safety, Tolerability, and Efficacy of Saroglitazar Mg 4 mg in Liver Transplant Recipients With Nonalcoholic Fatty Liver Disease (NAFLD)

NCT03639623
View directory record Official record
Conditions
Liver Transplant; Complications, NAFLD
Interventions
Saroglitazar
Drug
Lead sponsor
Zydus Therapeutics Inc.
Industry
Eligibility
18 Years to 75 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
1
States / cities
Richmond, Virginia
Source: ClinicalTrials.gov public record
Updated Oct 24, 2024 · Synced Oct 20, 2026, 4:04 AM EDT
Completed Phase 4 Interventional Results available

Sofosbuvir Based DAA Therapy in HIV/HCV Coinfected Pre or Post Liver Transplant

NCT02533934
View directory record Official record
Conditions
HIV, Hepatitis C, Cirrhosis
Interventions
Harvoni
Drug
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years and older
Enrollment
68 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2019
U.S. locations
8
States / cities
San Francisco, California • Washington D.C., District of Columbia • Baltimore, Maryland + 3 more
Source: ClinicalTrials.gov public record
Updated Feb 2, 2021 · Synced Oct 20, 2026, 4:04 AM EDT
Recruiting Not applicable Interventional

Normothermic Machine Perfusion of Steatotic Livers for Expansion of Donor Organ Pool

NCT06088758
View directory record Official record
Conditions
Liver Transplant
Interventions
Normothermic machine perfusion (NMP) of steatotic liver
Device
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years to 80 Years
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Nov 3, 2025 · Synced Oct 20, 2026, 4:04 AM EDT
Not listed Phase 1 Interventional

Use of Direct Peritoneal Resuscitation in High-risk Liver Transplant Recipients

NCT05195125
View directory record Official record
Conditions
End Stage Liver DIsease, Obesity, Acute Kidney Injury
Interventions
Direct Peritoneal Resuscitation
Procedure
Lead sponsor
University of Colorado, Denver
Other
Eligibility
18 Years and older
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
1
States / cities
Aurora, Colorado
Source: ClinicalTrials.gov public record
Updated Jun 8, 2023 · Synced Oct 20, 2026, 4:04 AM EDT
Terminated Phase 1Phase 2 Interventional Results available

Phase 1-2 Trial HCQ Plus TACE in Unresectable HCC

NCT02013778
View directory record Official record
Conditions
Hepatocellular Carcinoma
Interventions
HCQ
Drug
Lead sponsor
Abramson Cancer Center at Penn Medicine
Other
Eligibility
18 Years and older
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2019
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Apr 20, 2020 · Synced Oct 20, 2026, 4:04 AM EDT
Completed Not applicable Interventional Results available

Improving Medication Adherence in Adolescents Who Had a Liver Transplant

NCT03691220
View directory record Official record
Conditions
Transplant
Interventions
Telemetric Intervention
Behavioral
Lead sponsor
Icahn School of Medicine at Mount Sinai
Other
Eligibility
12 Years to 19 Years
Enrollment
148 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2025
U.S. locations
12
States / cities
Los Angeles, California • San Francisco, California • Miami, Florida + 7 more
Source: ClinicalTrials.gov public record
Updated Sep 30, 2026 · Synced Oct 20, 2026, 4:04 AM EDT
Completed No phase listed Observational

Genetic Predisposition-Chronic Nephrotoxicity From CI-Liver Transplant Recipients-Potential Correlation-Urinary Biomarkers

NCT00857844
View directory record Official record
Conditions
Complication of Transplanted Liver
Interventions
Not listed
Lead sponsor
Northwestern University
Other
Eligibility
18 Years and older
Enrollment
207 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2012
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated May 3, 2013 · Synced Oct 20, 2026, 4:04 AM EDT
Completed Phase 3 Interventional Results available

A Study of of Glecaprevir/Pibrentasvir in Adults With Chronic Hepatitis C Virus (HCV) Genotype 5 or 6 Infection

NCT02966795
View directory record Official record
Conditions
Hepatitis C Virus (HCV)
Interventions
Glecaprevir/Pibrentasvir
Drug
Lead sponsor
AbbVie
Industry
Eligibility
18 Years and older
Enrollment
84 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
6
States / cities
San Diego, California • San Francisco, California • West Hollywood, California + 2 more
Source: ClinicalTrials.gov public record
Updated Jul 30, 2021 · Synced Oct 20, 2026, 4:04 AM EDT